Clinical Trial: A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)

U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07780669) titled 'A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)' on Aug. 19.

Brief Summary: The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.

Study Start Date: Aug. 31

Study Type: INTERVENTIONAL

Condition: Pulmonary Disease, Chronic Obstructive

Intervention: DRUG: GSK5784283

GSK5784283 will be administered.

DRUG: Placebo

Placebo will be administered....